格隆汇12月8日丨太龙药业(600222.SH)公布，2025年12月8日，公司接到控股股东泰容产投通知，其筹 划的可能导致公司控制权变更的事项已与相关方达成一致并签署协议。根据《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第4号——停复牌》等相关规定，经公司向上海证券交 易所申请，公司股票将于2025年12月9日（星期二）开市起复牌。 ...

太龙药业公告，公司控股股东郑州泰容产业投资有限公司筹划的可能导致公司控制权变更的事项已与相 关方达成一致并签署协议。公司股票将于2025年12月9日开市起复牌。 ...

太龙药业公告，公司控股股东郑州泰容产业投资有限公司、持股5%以上的股东郑州众生实业集团有限 公司与江药集团江西医药控股有限公司签署了《股份转让协议》，泰容产投将持有的公司5010万股股份 （占公司当前总股本的8.73%）以11.04元/股的价格分两次转让给江药控股，总价款为5.53亿元。第一次 交割数量为4230万股股份（占公司当前总股本的7.37%），第二次交割数量为780万股股份（占公司当 前总股本的1.36%）。此外，公司与江药控股签署了《附条件生效的股份认购协议》，江药控股拟以现 金方式全额认购公司向其发行的不超过7460.52万股股票。 ...

太龙药业公告，公司与江药控股签署了《附条件生效的股份认购协议》，江药控股拟以现金方式全额认 购公司2025年度向特定对象发行的A股股票，认购金额不超过4.54亿元，认购数量不超过7460.52万股。 本次发行股票的价格为6.09元/股。 ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇12月8日丨太龙药业(600222.SH)公布2025年度向特定对象发行A股股票预案，本次向特定对象发 行A股股票的发行对象为江药控股，发行对象拟以现金方式认购本次发行的全部A股股票。江药控股与 公司签署了《附条件生效的股份认购协议》。本次向特定对象发行A股股票募集资金总额不超过4.54亿 元（含本数），扣除发行费用后将用于补充流动资金和偿还有息负债。若本次向特定对象发行A股股票 募集资金总额因监管政策变化或根据发行注册文件的要求予以调整的，则届时将相应调整。 ...

格隆汇12月8日丨太龙药业(600222.SH)公布2025年度向特定对象发行A股股票预案，本次向特定对象发 行A股股票的发行对象为江药控股，发行对象拟以现金方式认购本次发行的全部A股股票。江药控股与 公司签署了《附条件生效的股份认购协议》。本次向特定对象发行A股股票募集资金总额不超过4.54亿 元（含本数），扣除发行费用后将用于补充流动资金和偿还有息负债。若本次向特定对象发行A股股票 募集资金总额因监管政策变化或根据发行注册文件的要求予以调整的，则届时将相应调整。 ...

Group 1 - The company is undergoing a significant matter involving the transfer of shares by its controlling shareholder, which may lead to a change in control [2][3] - The company's stock will be suspended from trading starting December 2, 2025, for a period not exceeding two trading days due to the uncertainty surrounding the share transfer [2] - The company has applied for an extension of the trading suspension until December 4, 2025, as discussions with the transaction parties are ongoing and internal approval processes are required [3] Group 2 - The company will continue to fulfill its information disclosure obligations during the suspension period, providing updates based on the progress of the matter [3] - Investors are advised to pay attention to subsequent announcements regarding the matter and to be aware of potential investment risks [4]

Policy Developments - The National Healthcare Security Administration announced five typical cases of fraud involving maternity insurance funds, urging insured units and individuals to participate legally and provide accurate application materials to safeguard the fund [1] Drug and Device Approvals - Dongcheng Pharmaceutical's subsidiary received a production license for radioactive drugs, with expectations that it will not significantly impact current performance until commercial production is approved [1] - Jianyou Co., Ltd. received FDA approval for its propofol emulsion injection, with an investment of approximately RMB 73.66 million in R&D, and plans to launch the product in the U.S. soon [2] - Aihong Pharmaceutical presented clinical trial data for APL-1401 at the European Colorectal Congress, focusing on treating moderate to severe ulcerative colitis [6] - Fosun Pharma's subsidiary received approval for clinical trials of FXS887, an innovative drug for treating advanced malignant solid tumors [7] - Xinlitai received approval for clinical trials of SAL0140, a novel drug for chronic kidney disease, which could provide new treatment options if successful [8] Capital Market Activities - Lexin Medical announced that its controlling shareholder, Pan Weichao, has released the pledge on 18.71 million shares, which is 28.01% of his holdings and 8.56% of the total share capital [3] - Berry Genomics reported a decrease in the shareholding ratio of its controlling shareholder, Gao Yang, to 6.90% due to stock pledge defaults, with no significant adverse impact on the company's operations [4] - Tailong Pharmaceutical is planning a major matter that may lead to a change in control, with stock suspension expected to last no more than three trading days [5] Strategic Collaborations - JD Health and Boehringer Ingelheim Animal Health signed a strategic cooperation agreement to enhance the quality development of the domestic pet health industry through resource integration and complementary advantages [10] Regulatory Actions - Guizhou Bai Ling's actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading and other violations, which does not affect the company's daily operations [11]

Core Viewpoint - Tai Long Pharmaceutical is undergoing a potential change in control due to the share transfer plan by its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd. [1][3] Company Overview - Tai Long Pharmaceutical, established in 1993 and listed in 1999, is the first publicly traded pharmaceutical company in Henan Province, headquartered in Zhengzhou [2][4]. - The company operates three core business segments: pharmaceutical preparations, traditional Chinese medicine pieces, and pharmaceutical research and development services [2][4]. Business Operations - The pharmaceutical preparations segment primarily focuses on traditional Chinese medicine oral preparations, covering various therapeutic areas including respiratory, cardiovascular, digestive, neurological, reproductive systems, and applications for elderly, gynecology, and pediatrics [2][4]. - Key products include the Double Huang Lian Oral Liquid series, Double Jin Lian Compound, Children's Compound Chicken Inner Gold Chewable Tablets, Danshen Oral Liquid, Sheng Mai Drink, Huoxiang Zhengqi Compound, and Wuzi Yanzong Oral Liquid [2][4]. - The core product, Double Huang Lian Oral Liquid, has been repeatedly included in major epidemic treatment plans by the National Health Commission and the State Administration of Traditional Chinese Medicine, recognized as a representative medication for respiratory infectious public health events [2][4]. Financial Performance - In 2022, Tai Long Pharmaceutical experienced a significant profit decline, with net profit attributable to shareholders dropping by 1303.26% [5]. - For the first three quarters of 2023, the company reported revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit of 25.3255 million yuan, down 12.36% year-on-year [5]. - The company faces challenges due to the gradual implementation of industry policies, including the incomplete rollout of centralized procurement for traditional Chinese medicine, consolidation of retail channels, and intensified market competition [5].

Core Viewpoint - The stock price of Tailong Pharmaceutical (600222) has been rising due to the rapid increase in national flu activity, but the company has chosen to suspend trading amid plans for a potential change in control through a share transfer by its major shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd [1][5][6]. Group 1: Company Overview - Tailong Pharmaceutical was established in 1998 and went public in November 1999. Its main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [6][18]. - The company's drug manufacturing business has been a significant contributor, accounting for over 75% of total sales, with the core product, Shuanghuanglian Oral Liquid, being a recommended medication for major epidemic treatment plans [6][18]. Group 2: Recent Developments - The company announced a trading suspension starting December 2, 2025, due to the planned share transfer that may lead to a change in control [1][4]. - The stock price increased by over 30% leading up to the suspension, with a closing price of 8.58 yuan per share and a market capitalization of approximately 4.924 billion yuan on December 1, 2025 [7][19]. Group 3: Financial Performance - In 2024, Tailong Pharmaceutical reported revenue of 1.941 billion yuan, a year-on-year decrease of 6.21%. For the first three quarters of 2025, revenue continued to decline to 1.187 billion yuan, down 11.47% year-on-year [7][19]. - The net profit for 2022-2024 and the first three quarters of 2025 were -76 million yuan, 45 million yuan, 53 million yuan, and 30 million yuan, respectively, showing a significant recovery in 2023 but a slowdown in growth thereafter [20][23].